重组人尿激酶原在下肢深静脉血栓形成置管溶栓中的疗效

doi:10.3969/j.issn.1671-7171.2022.07.006

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1189 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨重组人尿激酶原(rhPro-UK)在急性下肢深静脉血栓形成置管溶栓中的临床疗效。【方法】回顾分析59例接受置管溶栓的急性下肢深静脉血栓患者的相关资料,其中30例接受尿激酶(UK)溶栓(A组),29例接受rhPro-UK溶栓(B组)。比较两组患者治疗后患肢静脉通畅评分、健患肢周径差值及并发症发生情况。【结果】溶栓后,A组静脉通畅评分为(2.33±1.24)分,明显高于B组的(1.69±0.85)分,且差异有统计学意义(P<0.05)。治疗后,A组股部周径差值和小腿周径差值分别为(1.18±1.00)cm和(1.03±0.61)cm,均高于B组的(0.64±0.63)cm和(0.71±0.47)cm,且差异均有统计学意义(P<0.05)。A组并发症总发生率为30.00%(9/30),高于B组的20.69%(6/29),但差异无统计学意义(P>0.05)。【结论】在急性下肢深静脉血栓置管溶栓治疗中,应用rhPro-UK治疗的溶栓效率高于UK治疗,值得临床借鉴。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：下肢/血液供给, 静脉血栓形成, 尿激酶型纤溶酶原激活物, 血栓溶解疗法/方法

Abstract：【Objective】 To investigate the clinical efficacy of recombinant human prourokinase (rhPro-UK) in catheter thrombolysis of acute lower extremity deep venous thrombosis. 【Methods】The data of 59 patients with acute deep venous thrombosis (DVT) were retrospectively analyzed. Among them,30 patients received urokinase (UK) thrombolysis (group A) and 29 patients received rhPro-UK thrombolysis (group B). The venous patency score of the affected limb,the difference of the peripheral diameter of the healthy limb and the complications were compared between the two groups. 【Results】 After thrombolysis,the score of venous patency in the group A was (2.33±1.24),which was significantly higher than that in the group B (1.69±0.85),and the difference was statistically significant (P<0.05). After treatment,the difference of femoral circumference and calf circumference in the group A were (1.18±1.00) cm and (1.03±0.61)cm respectively,which were higher than those in the group B (0.64±0.63) cm and (0.71±0.47) cm,and the difference between the two groups was statistically significant (P<0.05). The total incidence of complications in the group A was 30.00% (9/30),higher than 20.69% (6/29) in the group B,but the difference was not statistically significant (P>0.05). 【Conclusion】 In the thrombolytic therapy of acute deep venous thrombosis of lower limbs,the thrombolytic efficiency of rhPro-UK is higher than that of UK,it is worth using.

Key words： Lower Extremity/BS Venous Thrombosis Urokinase-Type Plasminogen Activator Thrombolytic Therapy/MT

收稿日期: 2022-02-15

中图分类号:

R364.15

基金资助:汉中市中心医院院级科研基金中标项目(No.YK2028)

通讯作者: **E-mail:lanpi2002@163.com

引用本文:

沈勇, 郑清华, 杨艳, 权建军, 崔文宁, 李兰兰. 重组人尿激酶原在下肢深静脉血栓形成置管溶栓中的疗效[J]. 医学临床研究, 2022, 39(7): 981-983.
SHEN Yong, ZHENG Qing-hua, YANG Yan,et al. Effect of Recombinant Human Prourokinase on Thrombolytic Therapy in Deep Venous Thrombosis of Lower Extremities. JOURNAL OF CLINICAL RESEARCH, 2022, 39(7): 981-983.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2022.07.006 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2022/V39/I7/981